Journal
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
Volume 34, Issue 6, Pages -Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/j.urolonc.2016.01.007
Keywords
Renal cell carcinoma; Adipokine; Obesity; Biomarker
Categories
Funding
- Korean Urological Oncology Society Research Fund [KUOS13-03]
- Bio & Medical Technology Development Program of the National Research Foundation (NRF) - Ministry of Science, ICT & Future Planning, South Korea [NRF-2014M3A9D3033887]
Ask authors/readers for more resources
Objective: To assess the association and prognostic value of adipokines (adipocyte-secreted peptide hormones) in renal cell carcinoma (RCC). Materials and methods: Plasma samples from 54 RCC patients and 25 age-matched healthy controls were analyzed for levels of adipokines (adiponectin, leptin, retinol-binding protein 4 [RBP4], and nicotinamide phosphoribosyltransferase [NAMPT]). Baseline characteristics and adipokine levels were compared between patients and controls. The effect of adipokine levels on RCC severity was also investigated. Results: Medians (patients/controls) were body mass index: 24.6/23.5 kg/m(2), serum glucose: 111/93 mg/dl, and high-density lipoprotein: 43/53 mg/dl, and significantly differed between the 2 groups. Median levels (patients/controls) of adipokines were adiponectin: 4.36/8.84 ug/ml, leptin: 2.91/2.92 ng/ml, RBP4: 30.27/16.17 ug/ml and NAMPT: 2.26/2.06 ng/ml; adiponectin, RBP4 and NAMPT (but not leptin) were independently associated with RCC in logistic regression models, and only serum NAMPT was significantly associated with RCC severity (T stage). Conclusions: Lower plasma levels of adiponectin, and higher levels of RBP4 and NAMPT, are strongly correlated with RCC, indicating that these adipokines could be used as biomarkers for RCC. (c) 2016 Elsevier Inc. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available